Company registration number SC616520 (Scotland)
LASER ENDOUROLOGY UK LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
PAGES FOR FILING WITH REGISTRAR
LASER ENDOUROLOGY UK LIMITED
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 7
LASER ENDOUROLOGY UK LIMITED
BALANCE SHEET
AS AT 31 MARCH 2025
31 March 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Tangible assets
3
78,605
103,209
Investments
4
15,000
15,000
93,605
118,209
Current assets
Debtors
5
53,175
50,368
Cash at bank and in hand
5,746
32,780
58,921
83,148
Creditors: amounts falling due within one year
6
(66,494)
(68,453)
Net current (liabilities)/assets
(7,573)
14,695
Total assets less current liabilities
86,032
132,904
Creditors: amounts falling due after more than one year
7
(63,639)
(78,637)
Provisions for liabilities
(19,647)
(25,798)
Net assets
2,746
28,469
Capital and reserves
Called up share capital
8
101
101
Profit and loss reserves
2,645
28,368
Total equity
2,746
28,469
LASER ENDOUROLOGY UK LIMITED
BALANCE SHEET (CONTINUED)
AS AT 31 MARCH 2025
31 March 2025
- 2 -

For the financial year ended 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved and signed by the director and authorised for issue on 17 December 2025
Dr F  Al Jaafari
Director
Company registration number SC616520 (Scotland)
LASER ENDOUROLOGY UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
- 3 -
1
Accounting policies
Company information

Laser Endourology UK Limited is a private company limited by shares incorporated in Scotland. The registered office is 6 St Colme Street, Edinburgh, EH3 6AD.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for specialist medical services provided in the normal course of business.

1.3
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Computer equipment
33% straight line
Motor vehicles
20% straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.4
Fixed asset investments

Interests in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses. The investments are assessed for impairment at each reporting date and any impairment losses or reversals of impairment losses are recognised immediately in profit or loss.

1.5
Impairment of fixed assets

The carrying value of tangible fixed assets are reviewed for impairment when events or changes in circumstances indicate that the carrying value may not be recoverable.

1.6
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

LASER ENDOUROLOGY UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
1
Accounting policies
(Continued)
- 4 -
1.7
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Debtors

Debtors with no stated interest rate or receivable within one year are recorded at transaction price. Any losses arising from impairment are recognised in the profit and loss account.

Creditors

Creditors with no stated interest rate and payable within one year are recorded at transaction price.

 

All interest bearing loans and borrowings which are basic financial instruments are initially recorded at the present value of cash payable. After initial recognition they are measured at amortised cost.

1.8
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.9
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

LASER ENDOUROLOGY UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
1
Accounting policies
(Continued)
- 5 -
1.10
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.11
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.12
Leases

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
2
2
3
Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 April 2024
125,225
Additions
1,196
At 31 March 2025
126,421
Depreciation and impairment
At 1 April 2024
22,016
Depreciation charged in the year
25,800
At 31 March 2025
47,816
Carrying amount
At 31 March 2025
78,605
At 31 March 2024
103,209
LASER ENDOUROLOGY UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 6 -
4
Fixed asset investments
2025
2024
£
£
Shares in group undertakings and participating interests
15,000
15,000
5
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
16,552
24,530
Other debtors
36,623
25,838
53,175
50,368
6
Creditors: amounts falling due within one year
2025
2024
£
£
Taxation and social security
47,598
43,494
Other creditors
18,896
24,959
66,494
68,453
7
Creditors: amounts falling due after more than one year
2025
2024
£
£
Other creditors
63,639
78,637
8
Called up share capital
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
A ordinary shares of £1 each
45
45
45
45
B ordinary shares of £1 each
45
45
45
45
C ordinary shares of £1 each
5
5
5
5
D ordinary shares of £1 each
5
5
5
5
E ordinary shares of £1 each
1
1
1
1
101
101
101
101
LASER ENDOUROLOGY UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 7 -
9
Related party transactions

The director is of the opinion that all related party transactions are conducted under normal market conditions and on an arm's length basis and therefore do not need to be disclosed under FRS 102 section 1A appendix C.

2025-03-312024-04-01falsefalsefalse17 December 2025CCH SoftwareCCH Accounts Production 2025.300No description of principal activityDr F Al JaafariSC6165202024-04-012025-03-31SC6165202025-03-31SC6165202024-03-31SC616520core:OtherPropertyPlantEquipment2025-03-31SC616520core:OtherPropertyPlantEquipment2024-03-31SC616520core:CurrentFinancialInstrumentscore:WithinOneYear2025-03-31SC616520core:CurrentFinancialInstrumentscore:WithinOneYear2024-03-31SC616520core:WithinOneYear2025-03-31SC616520core:WithinOneYear2024-03-31SC616520core:AfterOneYear2025-03-31SC616520core:AfterOneYear2024-03-31SC616520core:CurrentFinancialInstruments2025-03-31SC616520core:CurrentFinancialInstruments2024-03-31SC616520core:ShareCapital2025-03-31SC616520core:ShareCapital2024-03-31SC616520core:RetainedEarningsAccumulatedLosses2025-03-31SC616520core:RetainedEarningsAccumulatedLosses2024-03-31SC616520core:ShareCapitalOrdinaryShareClass12025-03-31SC616520core:ShareCapitalOrdinaryShareClass12024-03-31SC616520core:ShareCapitalOrdinaryShareClass22025-03-31SC616520core:ShareCapitalOrdinaryShareClass22024-03-31SC616520core:ShareCapitalOrdinaryShareClass32025-03-31SC616520core:ShareCapitalOrdinaryShareClass32024-03-31SC616520core:ShareCapitalOrdinaryShareClass42025-03-31SC616520core:ShareCapitalOrdinaryShareClass42024-03-31SC616520core:ShareCapitalOrdinaryShareClass52025-03-31SC616520core:ShareCapitalOrdinaryShareClass52024-03-31SC616520core:ShareCapitalOrdinaryShares2025-03-31SC616520core:ShareCapitalOrdinaryShares2024-03-31SC616520bus:Director12024-04-012025-03-31SC616520core:ComputerEquipment2024-04-012025-03-31SC616520core:MotorVehicles2024-04-012025-03-31SC6165202023-04-012024-03-31SC616520core:OtherPropertyPlantEquipment2024-03-31SC616520core:OtherPropertyPlantEquipment2024-04-012025-03-31SC616520core:Non-currentFinancialInstruments2025-03-31SC616520core:Non-currentFinancialInstruments2024-03-31SC616520bus:OrdinaryShareClass12024-04-012025-03-31SC616520bus:OrdinaryShareClass22024-04-012025-03-31SC616520bus:OrdinaryShareClass32024-04-012025-03-31SC616520bus:OrdinaryShareClass42024-04-012025-03-31SC616520bus:OrdinaryShareClass52024-04-012025-03-31SC616520bus:OrdinaryShareClass12025-03-31SC616520bus:OrdinaryShareClass12024-03-31SC616520bus:OrdinaryShareClass22025-03-31SC616520bus:OrdinaryShareClass22024-03-31SC616520bus:OrdinaryShareClass32025-03-31SC616520bus:OrdinaryShareClass32024-03-31SC616520bus:OrdinaryShareClass42025-03-31SC616520bus:OrdinaryShareClass42024-03-31SC616520bus:OrdinaryShareClass52025-03-31SC616520bus:OrdinaryShareClass52024-03-31SC616520bus:AllOrdinaryShares2025-03-31SC616520bus:AllOrdinaryShares2024-03-31SC616520bus:PrivateLimitedCompanyLtd2024-04-012025-03-31SC616520bus:FRS1022024-04-012025-03-31SC616520bus:AuditExemptWithAccountantsReport2024-04-012025-03-31SC616520bus:SmallCompaniesRegimeForAccounts2024-04-012025-03-31SC616520bus:FullAccounts2024-04-012025-03-31xbrli:purexbrli:sharesiso4217:GBP